Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 9/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.37 |
| ▸ | CDK2 | P24941 | 7/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675895 | 0.91 | CDK2 (0.38) | MAPK1CCNE1CDK2 | |
| SCHEMBL18556886 | 0.88 | CCNE1 (0.38) | MAPK1CCNE1CDK2 | |
| SCHEMBL16675905 | 0.84 | MAPK1 (0.45) | MAPK1 | |
| SCHEMBL16675900 | 0.83 | JAK3 (0.36) | MAPK1CDK2JAK3GSK3B | |
| SCHEMBL16675903 | 0.81 | MAPK1 (0.39) | MAPK1CCNE1CDK2 | |
| SCHEMBL16675930 | 0.81 | JAK3 (0.37) | CCNE1CDK2JAK3GSK3B | |
| SCHEMBL16675920 | 0.80 | CDK2 (0.39) | MAPK1CCNE1CDK2 | |
| SCHEMBL16675893 | 0.80 | MAPK1 (0.38) | MAPK1CCNE1CDK2 | |
| SCHEMBL16675925 | 0.79 | CDK2 (0.39) | MAPK1CCNE1CDK2 | |
| SCHEMBL16675908 | 0.79 | MAPK1 (0.39) | MAPK1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | MAPK1 3291/4885CCNE1 3962/4885CDK2 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.